

COPD Drug Market Opportunity & Clinical Pipeline Analysis

<https://marketpublishers.com/r/C63A47F3174EN.html>

Date: April 2014

Pages: 590

Price: US\$ 2,200.00 (Single User License)

ID: C63A47F3174EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Close to 1 Billion people worldwide suffer from respiratory or pulmonary diseases. In the respiratory therapeutic domain, Asthma and COPD are the major categories, accounting for close to 75% of the total patient for respiratory or pulmonary diseases. Chronic obstructive pulmonary disease (COPD) is a disease which progresses in the lungs and requires treatment all through the life. It is an inflammatory disorder which is characterized by obstruction in the variable airflow and airway hyper-responsiveness to many intrinsic, genetic and environmental stimuli. These disorders have become one of the major reasons for disability and death. The prevalence and incidence of this disease is increasing worldwide.

Bronchodilators and polypharmacy dominates the treatment for this disease. It is expected that by 2020, COPD would account for more than 6 Million deaths across the globe annually. In spite of significant investments in the development of novel agents to treat the disease, the COPD therapy area is generally dominated by inhaled bronchodilator therapies which only relieve symptoms, but do not completely cure the disease. There exist many opportunities for a disease-modifying therapy. However, the development of new COPD therapies is increasingly focusing on therapies which combine two bronchodilators into one inhaler.

There has been significant expansion in the COPD drug market in the recent years and it is expected that this market would record high growth over the next decade. The major driving force in the future would be a greater demand for new drugs with higher and better efficiency. This market has been recognized to be one with many opportunities which are yet to be tapped. Hence, the leading pharma companies are

increasing their focus on this segment by introducing new combination drugs and novel agents. The global market for COPD has been estimated to be close to US\$ 12 billion in 2013. With a high number of new and more efficient and convenient drugs crowding the market, it is expected that this market would grow at a CAGR of 8% to reach close to US\$ 17.5 billion by 2018.

“COPD Drug Market Opportunity & Clinical Pipeline Analysis” Report Highlight:

COPD Drug Market Overview

COPD Patient Base: Global, US & Europe

FDA & EMA Guidelines on Clinical Investigation of COPD Drugs

COPD Drug Clinical Pipeline by Phase & Country

COPD Drug in Development Phase: 174

Majority of COPD Drugs in Preclinical Phase: 72

Marketed COPD Drugs: 36

Discontinued & Suspended COPD Drug Profiles

Contents

1. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE MARKET OVERVIEW

- 1.1 Market Overview
- 1.2 Clinical Trial Analysis

2. EMA GUIDELINE ON CLINICAL INVESTIGATION OF COPD DRUGS

- 2.1 Introduction
- 2.2 Legal Basis & Relevant Guidelines
- 2.3 Patient Characteristics & Selection Of Patients
- 2.4 Methods to Assess Efficacy
- 2.5 Strategy & Design Of Clinical Trials
- 2.6 Safety

3. FDA GUIDELINE ON CLINICAL INVESTIGATION OF COPD DRUGS

- 3.1 Disease Target and Indication
- 3.2 Types of Drugs for COPD
- 3.3 Drug Development Population
- 3.4 Dose Selection
- 3.5 Efficacy Assessment
- 3.6 Recommended Primary and Secondary Efficacy Endpoints
- 3.7 Study Duration
- 3.8 Number of Studies
- 3.9 Considerations Regarding Demonstration of Efficacy
- 3.10 Considerations Regarding Demonstration of Safety
- 3.11 Specific Efficacy Study Considerations

4. CHRONIC OBSTRUCTIVE PULMONARY DISEASE DRUG CLINICAL TRIAL BY PHASE & COUNTRY

- 4.1 Phase Unknown
- 4.2 Research
- 4.3 Preclinical
- 4.4 Clinical
- 4.5 Phase I

- 4.6 Phase I/II
- 4.7 Phase II
- 4.8 Phase III
- 4.9 Preregistration
- 4.10 Registered

5. MARKETED DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY COUNTRY

6. NO DEVELOPMENT, DISCONTINUED & SUSPENDED DRUG CLINICAL TRIAL BY PHASE & COUNTRY

- 6.1 No Development Reported
- 6.2 Discontinued
- 6.3 Market Withdrawal
- 6.4 Suspended

7. COMPETITIVE LANDSCAPE

- 7.1 Almirall
- 7.2 AstraZeneca
- 7.3 Boehringer Ingelheim
- 7.4 Bayer
- 7.5 Chiesi Farmaceutici
- 7.6 Forest Laboratories
- 7.7 Lallemand Pharma
- 7.8 Merck & Co
- 7.9 Novartis
- 7.10 Sunovion Pharmaceuticals

List Of Figures

LIST OF FIGURES

- Figure 1-1: Global - People Suffering With COPD (Million), 2013-2018
- Figure 1-2: US - People Suffering With COPD (Million), 2013-2018
- Figure 1-3: US - People Suffering With COPD by Age Group (%)
- Figure 1-4: Europe - People Suffering With COPD (Million), 2013-2018
- Figure 1-5: Europe – Death from COPD ('000) , 2005 & 2030
- Figure 1-6: Global COPD Drug Market (US\$ Billion), 2012-2018
- Figure 1-7: Number of COPD Drugs in Clinical Trial by Phase, 2014
- Figure 1-8: COPD Drugs in Clinical Trial by Phase (%), 2014
- Figure 1-9: Number of Discontinued COPD Drugs in Clinical Trial by Phase, 2014
- Figure 1-10: Discontinued COPD Drugs in Clinical Trial by Phase (%), 2014
- Figure 1-11: Number of Suspended COPD Drugs in Clinical Trial by Phase, 2014
- Figure 1-12: Suspended COPD Drugs in Clinical Trial by Phase (%), 2014
- Figure 1-13: Number of No Development in COPD Drugs in Clinical Trial by Phase, 2014
- Figure 1-14: No Development in COPD Drugs in Clinical Trial by Phase (%), 2014

I would like to order

Product name: COPD Drug Market Opportunity & Clinical Pipeline Analysis

Product link: <https://marketpublishers.com/r/C63A47F3174EN.html>

Price: US\$ 2,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C63A47F3174EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970